Cargando…

ID4 regulates transcriptional activity of wild type and mutant p53 via K373 acetylation

Given that mutated p53 (50% of all human cancers) is over-expressed in many cancers, restoration of mutant p53 to its wild type biological function has been sought after as cancer therapy. The conformational flexibility has allowed to restore the normal biological function of mutant p53 by short pep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morton, Derrick J, Patel, Divya, Joshi, Jugal, Hunt, Aisha, Knowell, Ashley E, Chaudhary, Jaideep
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356822/ https://www.ncbi.nlm.nih.gov/pubmed/27911860 http://dx.doi.org/10.18632/oncotarget.13701

Ejemplares similares

Id4 dependent acetylation restores mutant-p53 transcriptional activity
por: Knowell, Ashley E, et al.
Publicado: (2013)

Intra-tumoral delivery of functional ID4 protein via PCL/maltodextrin nano-particle inhibits prostate cancer growth
por: Korang-Yeboah, Maxwell, et al.
Publicado: (2016)

Id4 deficiency attenuates prostate development and promotes PIN-like lesions by regulating androgen receptor activity and expression of NKX3.1 and PTEN
por: Sharma, Pankaj, et al.
Publicado: (2013)

Id1 and Id3 expression is associated with increasing grade of prostate cancer: Id3 preferentially regulates CDKN1B
por: Sharma, Pankaj, et al.
Publicado: (2012)

Inactivation of ID4 promotes a CRPC phenotype with constitutive AR activation through FKBP52
por: Joshi, Jugal Bharat, et al.
Publicado: (2017)

Epigenetic inactivation of inhibitor of differentiation 4 (Id4) correlates with prostate cancer
por: Sharma, Pankaj, et al.
Publicado: (2012)

The helix-loop-helix transcriptional regulator Id4 is required for terminal differentiation of luminal epithelial cells in the prostate
por: Hewa Bostanthirige, Dhanushka, et al.
Publicado: (2021)

EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4 in prostate cancer
por: Chinaranagari, Swathi, et al.
Publicado: (2014)

Inhibitor of differentiation 1 (Id1) promotes cell survival and proliferation of prostate epithelial cells
por: Schmidt, Michelle, et al.
Publicado: (2010)

Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation
por: Kong, Li Ren, et al.
Publicado: (2020)

A Modified Coupled Spectrophotometric Method to Detect 2-5 Oligoadenylate Synthetase Activity in Prostate Cell Lines
por: Bhosle, Sushma M., et al.
Publicado: (2016)

PM373. Behavioral and neurochemical abnormalities in heterozygous Reelin Orleans mutant mouse model of schizophrenia
por: Yamada, Kiyofumi, et al.
Publicado: (2016)

Inhibitor of differentiation 4 (Id4) is a potential tumor suppressor in prostate cancer
por: Carey, Jason PW, et al.
Publicado: (2009)

Suberoylanilide hydroxamic acid enhances the radiosensitivity of lung cancer cells through acetylated wild-type and mutant p53-dependent modulation of mitochondrial apoptosis
por: Wu, Kan, et al.
Publicado: (2021)

Violin concerto no. 3, K. 216 ; Violin concerto no. 5, K. 219 ; Adagio, K. 261 ; Rondo, K. 373
por: Mozart, Wolfgang Amadeus, 1756-1791
Publicado: (1990)

Run 373P, both Rings
por: Schnell, Wolfgang
Publicado: (1973)

Editorial: Advances in wild type and mutant p53 research in cancer
por: Hernández-de la Cruz, Olga N., et al.
Publicado: (2022)

Diverse functions of miR-373 in cancer
por: Wei, Furong, et al.
Publicado: (2015)

Noncanonical DNA Motifs as Transactivation Targets by Wild Type and Mutant p53
por: Jordan, Jennifer J., et al.
Publicado: (2008)

Maspin subcellular expression in wild-type and mutant TP53 gastric cancers
por: Gurzu, Simona, et al.
Publicado: (2020)

Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer
por: Zhang, Shengliang, et al.
Publicado: (2022)

Structural Modeling of Wild and Mutant Forms of Human Plasma Platelet Activating Factor-Acetyl Hydrolase Enzyme
por: Khan, Mohd Imran, et al.
Publicado: (2020)

Inhibitor of DNA binding 2 (Id2) mediates microtubule polymerization in the brain by regulating αK40 acetylation of α-tubulin
por: Yun, Taegwan, et al.
Publicado: (2021)

NAT10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2
por: Liu, Xiaofeng, et al.
Publicado: (2016)

G9a stimulates CRC growth by inducing p53 Lys373 dimethylation-dependent activation of Plk1
por: Zhang, Jie, et al.
Publicado: (2018)

Correction: Noncanonical DNA Motifs as Transactivation Targets by Wild Type and Mutant p53
por: Jordan, Jennifer J., et al.
Publicado: (2008)

Temperature sensitivity of human wild-type and mutant p53 proteins expressed in vivo.
por: Ponchel, F., et al.
Publicado: (1998)

Correction: Noncanonical DNA Motifs as Transactivation Targets by Wild Type and Mutant p53
por: Jordan, Jennifer J., et al.
Publicado: (2008)

Chemokine Network and Overall Survival in TP53 Wild-Type and Mutant Ovarian Cancer
por: Ignacio, Rosa Mistica C., et al.
Publicado: (2018)

Mutant and Wild-Type Tumor Suppressor p53 Induces p300 Autoacetylation
por: Kaypee, Stephanie, et al.
Publicado: (2018)

Recent findings on the role of wild-type and mutant p53 in cancer development and therapy
por: Babamohamadi, Mehregan, et al.
Publicado: (2022)

Opposing Roles of Wild-type and Mutant p53 in the Process of Epithelial to Mesenchymal Transition
por: Semenov, Oleg, et al.
Publicado: (2022)

373 Alteration of Smell in Patients with Persistent Allergic Rhinitis
por: De Barayazarra, Susana, et al.
Publicado: (2012)

Correction to Lancet Psychiatry 2021; 8: 373–86
Publicado: (2022)

The Inhibition of Autophagy Sensitises Colon Cancer Cells with Wild-Type p53 but Not Mutant p53 to Topotecan Treatment
por: Li, Dan-Dan, et al.
Publicado: (2012)

Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1
por: Bollu, Lakshmi Reddy, et al.
Publicado: (2020)

Correction to: Inhibitor of DNA binding 2 (Id2) mediates microtubule polymerization in the brain by regulating αK40 acetylation of α-tubulin
por: Yun, Taegwan, et al.
Publicado: (2021)

Wild-type p53 oligomerizes more efficiently than p53 hot-spot mutants and overcomes mutant p53 gain-of-function via a “dominant-positive” mechanism
por: Walerych, Dawid, et al.
Publicado: (2018)

p53 Acetylation: Regulation and Consequences
por: Reed, Sara M., et al.
Publicado: (2014)

Insights into Regulators of p53 Acetylation
por: Nagasaka, Mai, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f9413hs1f4o1r3trk02cn223j0